Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web address) of an individual response, simply click on the response headline and copy the URL from the browser window. A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed and they are not journal articles. The BMJ reserves the right to remove responses which are being wilfully misrepresented as published articles.
This is another example of the bad face of Big Pharma. Last year there was a huge uproar by the Industry when the Indian Supreme court denied a 'patent' to Novartis for Imatinib. For similar reasons the Indian government granted compulsory licensing for the manufacture of Herceptin by Indian firms, at a fraction of cost of the Roche drug. This time another country (South Africa) has taken upon it the responsibility to ensure "patient-protection" over and above "patent-protection".
The growing tempers of patient groups and NGOs should make them cautious. It's time for Big Pharma to come clean about its acts and intentions. The purpose of providing effective and safe medicines at a reasonably fair cost to the majority of the world's population should not slip away from its mind. Or else we are going to see such instances more often in future.
No competing interests
11 February 2014
Government Medical College & Hospital , Chandigarh,India.
Government Medical College & Hospital , Chandigarh,India